ORTHOFIX MEDICAL INC
NASDAQ: OFIX (Orthofix Medical Inc.)
Last update: 7 hours ago16.01
-0.30 (-1.84%)
| Previous Close | 16.31 |
| Open | 16.18 |
| Volume | 168,632 |
| Avg. Volume (3M) | 200,958 |
| Market Cap | 624,750,208 |
| Price / Earnings (Forward) | 20.04 |
| Price / Sales | 0.800 |
| Price / Book | 1.30 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -15.76% |
| Operating Margin (TTM) | -3.59% |
| Diluted EPS (TTM) | -3.30 |
| Quarterly Revenue Growth (YOY) | 7.60% |
| Total Debt/Equity (MRQ) | 38.50% |
| Current Ratio (MRQ) | 2.57 |
| Operating Cash Flow (TTM) | 25.79 M |
| Levered Free Cash Flow (TTM) | 55.42 M |
| Return on Assets (TTM) | -4.50% |
| Return on Equity (TTM) | -22.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Orthofix Medical Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 5.33% |
| % Held by Institutions | 86.55% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rubric Capital Management Lp | 31 Dec 2024 | 3,694,946 |
| Engine Capital Management, Lp | 31 Dec 2024 | 3,450,744 |
| Paradigm Capital Management Inc/Ny | 31 Dec 2024 | 2,485,900 |
| Juniper Investment Company, Llc | 31 Dec 2024 | 1,937,249 |
| Boone Capital Management Llc | 31 Dec 2024 | 1,057,313 |
| Emerald Advisers, Llc | 31 Dec 2024 | 822,377 |
| Ayal Capital Advisors Ltd | 31 Dec 2024 | 539,871 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (Canaccord Genuity, 49.91%) | Buy |
| Median | 23.00 (43.66%) | |
| Low | 22.00 (Roth MKM, 37.41%) | Buy |
| Average | 23.00 (43.66%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 17.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 26 Feb 2025 | 24.00 (49.91%) | Buy | 17.26 |
| 22 Jan 2025 | 24.00 (49.91%) | Buy | 18.38 | |
| Roth MKM | 26 Feb 2025 | 22.00 (37.41%) | Buy | 17.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Mar 2025 | Announcement | Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System |
| 12 Mar 2025 | Announcement | Orthofix Announces Appointment of Vickie Capps to Board of Directors |
| 03 Mar 2025 | Announcement | Orthofix to Participate in the 37th Annual Roth Conference |
| 25 Feb 2025 | Announcement | Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance |
| 17 Feb 2025 | Announcement | Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference |
| 28 Jan 2025 | Announcement | Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |